Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02499081 · ClinicalTrials.gov registry record · Phase 2
UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment
A Phase 2 study, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT02499081 is a Phase 2 study that has completed, run by University of Arkansas. The registered enrollment target is 20 participants.
The verdict
NCT02499081, a Phase 2 study, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of Ixazomib on inducing osteoblast activation as measured by bone markers and imaging in patients with relapsed/refractory myeloma.
Interventions
- DRUG Ixazomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-09 |
| Est. Completion | 2018-05-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02499081
The ClinicalTrials.gov registry entry for NCT02499081 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ixazomib is the first listed.
NCT02499081 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02499081 about?
NCT02499081 is a clinical study titled "UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment". The purpose of this study is to evaluate the effect of Ixazomib on inducing osteoblast activation as measured by bone markers and imaging in patients with relapsed/refractory myeloma.
What is the current status of trial NCT02499081?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2015-09. Estimated completion is 2018-05-17.
What interventions are being tested in trial NCT02499081?
The interventions under investigation include: Ixazomib (DRUG).
Who is sponsoring clinical trial NCT02499081?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.